🇺🇸 FDA
Patent

US 12230379

Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

granted A61KA61K35/13A61K40/11

Quick answer

US patent 12230379 (Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy) held by Iovance Biotherapeutics, Inc. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Iovance Biotherapeutics, Inc.
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K35/13, A61K40/11, A61K40/42, A61P